Finland· FI-REL-REL47488
Ruconest
A conestat alfa product containing conestat alfa, registered in Finland by Orifarm Oy. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Conestat alfa is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC04 (conestat alfa), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Conestat alfa · ATC B06AC04
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Conestat alfa
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- B06AC04
- ATC class
- Conestat alfa
- Defined daily dose
- 3.5 TSD, E
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
47 interactions on record for conestat alfa.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Conestat alfa · interactions on record
47 records
- 5 severe
- 42 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Conestat alfa in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesRuconestPharming Healthcare Inc.
- ItalyBERINERT*1 flaconcino polv EV 1.500 UI + 1 flaconcino solv 3 ml + setCSL BEHRING GmbH
- SpainRUCONEST 2100 U POLVO PARA SOLUCION INYECTABLEPharming Group N.V.
- FranceRUCONEST 2100 U, poudre et solvant pour solution injectablePHARMING GROUP (PAYS-BAS)
- United KingdomRuconest 2,100unit powder and solvent for solution for injection vialsPharming Group N.V.
- IrelandRuconest 2100 Units powder and solvent for solution for injectionPharming Group N.V.
- IcelandRuconestPharming Group N.V.*
- NetherlandsRuconest, poeder en oplosmiddel voor oplossing voor injectiePharming Group N.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ruconest
- Liechtenstein · Ruconest
- Norway · Ruconest
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/40783b81-6d6c-47c9-a360-f90f1fad783c GET /v1/drugs/40783b81-6d6c-47c9-a360-f90f1fad783c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "3.5",
"form": "injektiokuiva-aine, liuosta varten",
"route": "Laskimoon",
"ddd_unit": "TU",
"strength": "2100 U",
"atc_label": "konestaatti alfa",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/10/641/001",
"fimea_rel_id": "REL47488",
"authorised_at": "2015-04-20"
}See everything about conestat alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.